BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210318
DTSTAMP:20260515T163040
CREATED:20201214T152316Z
LAST-MODIFIED:20201214T152538Z
UID:28302-1615766400-1616025599@www.pharmajournalist.com
SUMMARY:Targeting RNA Congress 2021
DESCRIPTION:Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins\, therefore making it an obvious target. With Risdiplam being approved by the FDA in August\, and several major collaborations also being penned throughout 2020\, including a $190 million deal between Arrakis and Roche\, it seems like a good time to target these protein precursors. \n \nThe Targeting RNA Congress will return for 2021\, March 15-17\, and will take a look at the latest techniques to analyse and predict protein structure\, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent\, rather than treat\, disease. \nKey Outcomes from the summit include: \n\nLearn where to target your RNA molecules after exploring the newest biophysical techniques to analyse RNA structure\, including NMR\, Cryo-EM\, and in silico modelling with Silvi Rouskin\, (MIT)\, Wah Chiu (Stanford University) and Hashim Al Hashimi (Duke University).\nUnderstand what makes a druggable RNA target and hear from expert RNA biologists to advise how best to drug your favourite RNA targets with Anima Biotech and Craig Blain (Arrakis).\nGet translational insights into what considerations are important when creating a small molecule that targets RNA by learning how to develop tools for assessment of RNA targets with Amanda Garner (University of Michigan)\nHear what new techniques can help to drug these tricky targets\, including RNAi\, RNA degraders and RIBOTACs with Gene Yeo (UCSD)\, Jonathan Hall (Zurich) and Matt Disney (Scripps and Expansion).\n\nTo know more about Targeting RNA Congress please click here.
URL:https://www.pharmajournalist.com/event/targeting-rna-congress-2021/
LOCATION:Virtual Summit EST Timezone
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210317
DTSTAMP:20260515T163040
CREATED:20201223T083652Z
LAST-MODIFIED:20201223T083652Z
UID:28371-1615766400-1615939199@www.pharmajournalist.com
SUMMARY:SMi’s 2nd Annual AI in Drug Discovery
DESCRIPTION:Chaired by: Darren Green\, Director of Molecular Design & Senior Fellow\, GSK \nSponsored by: OpenEye Scientific Software \nExploring the latest Innovations in Machine Learning for Enhancing Discovery Pipelines \nSMi is proud to present its 2nd Annual AI in Drug Discovery Conference\, taking place on the 15-16 March 2021. \nWith the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3\,900 million by 2027\, the conference agenda will encompass key drivers leading the way into a shorter\, cheaper\, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech\, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’. \n \nFurthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases\, and will highlight key case studies across these themes\, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail \nEvent Hashtag: #SMiAIDrugDis \nHIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscover the latest innovations in AI-based drug discovery platforms\nEngage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines\nUnderstand how AI can be effectively implemented to enhance productivity\nDelve into best practices in data quality\, curation\, and validation\nExplore how AI is being used to unlock therapies that have evaded traditional drug discovery\n\nKEY SPEAKERS INCLUDE \n\nNoor Shaker\, CEO\, Glamorous AI\nMaria Luisa Pineda\, Co-Founder & CEO\, Envisagenics\nEd Addison\, Co-founder\, Chairman\, and CEO\, Cloud Pharmaceuticals\nLiling Warren\, Director\, Head of Translational Medicine Statistics\, Teva Pharmaceuticals\nLili Peng\, Associate Director Scientific Ecosystem Analytics Lead\, Biogen\nMark De Pristo\, CEO\, BigHat Biosciences\nPhilipe Moingeon\, Head of Immuno-inflammation\, Servier\nHugo Ceulemans\, Scientific Director\, Discovery Data Sciences\, Janssen\nPeter Henstock\, Machine Learning & AI Lead\, Pfizer\nNaheed Kurji\, CEO\, Cyclica\n\nWHO SHOULD ATTEND \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-2nd-annual-ai-in-drug-discovery/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR